A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss

INTRODUCTION: The sodium-glucose cotransporter 2 inhibitor dapagliflozin and the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide reduce bodyweight via differing and complementary mechanisms. This post hoc analysis investigated the metabolic effects and baseline associations with bodyweigh...

Descripción completa

Detalles Bibliográficos
Autores principales: Pereira, Maria J., Lundkvist, Per, Kamble, Prasad G., Lau, Joey, Martins, Julian G., Sjöström, C. David, Schnecke, Volker, Walentinsson, Anna, Johnsson, Eva, Eriksson, Jan W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064580/
https://www.ncbi.nlm.nih.gov/pubmed/29949016
http://dx.doi.org/10.1007/s13300-018-0449-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064580/
https://www.ncbi.nlm.nih.gov/pubmed/29949016
http://dx.doi.org/10.1007/s13300-018-0449-6

Ejemplares similares